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Neuropathy Target Esterase Gene Mutations
Cause Motor Neuron Disease
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Colin Delaney,1 Rudy J. Richardson,1,2 James W. Albers,1 Nori Matsunami,3 Jeff Stevens,3
Hilary Coon,4 Mark Leppert,3 and John K. Fink1,5,*
The possibility that organophosphorus (OP) compounds contribute to motor neuron disease (MND) is supported by association of para-
oxonase 1 polymorphisms with amyotrophic lateral sclerosis (ALS) and the occurrence of MND in OP compound-induced delayed neu-
ropathy (OPIDN), in which neuropathy target esterase (NTE) is inhibited by organophosphorylation. We evaluated a consanguineous
kindred and a genetically unrelated nonconsanguineous kindred in which affected subjects exhibited progressive spastic paraplegia
and distal muscle wasting. Affected subjects resembled those with OPIDN and those with Troyer Syndrome due to SPG20/spartin
gene mutation (excluded by genetic linkage and SPG20/spartin sequence analysis). Genome-wide analysis suggested linkage to a
22 cM homozygous locus (D19S565 to D19S884, maximum multipoint LOD score 3.28) on chromosome 19p13 to which NTE had
been mapped (GenBank AJ004832). NTE was a candidate because of its role in OPIDN and the similarity of our patients to those
with OPIDN. Affected subjects in the consanguineous kindred were homozygous for disease-speciﬁc NTE mutation c.3034A/G that
disrupted an interspecies conserved residue (M1012V) in NTE’s catalytic domain. Affected subjects in the nonconsanguineous family
were compound heterozygotes: one allele had c.2669G/Amutation, which disrupts an interspecies conserved residue in NTE’s catalytic
domain (R890H), and the other allele had an insertion (c.2946_2947insCAGC) causing frameshift and protein truncation
(p.S982fs1019). Disease-speciﬁc, nonconserved NTE mutations in unrelated MND patients indicates NTE’s importance in maintaining
axonal integrity, raises the possibility that NTE pathway disturbances contribute to other MNDs including ALS, and supports the role of
NTE abnormalities in axonopathy produced by neuropathic OP compounds.Exposure to neurotoxic organophosphorous (OP) com-
pounds of sufﬁcient magnitude and duration causes neu-
rodegeneration in humans, livestock, and laboratory ani-
mals.1 OP compound exposures occur in industrial or
agricultural environments and as the consequences of
terrorism, accidents, suicide attempts, or chemical warfare.
Recent attention has focused on OP neurotoxicity after the
use of Sarin in the 1995 Tokyo subway terrorist incident2
and because of concerns about persistent neurological
effects after exposures to neurotoxic OP agents in the
Gulf War. During the Prohibition era in the United States,
consumption of Jamaica ginger extract (‘‘Ginger Jake’’)
adulterated with triorthocresyl phosphate (TOCP) led to
OP compound-induced delayed neuropathy (OPIDN) in an
estimated 50,000 Americans.3–5 Additional outbreaks of
OPIDN causing paralysis of tens of thousands of individuals
have occurred in Morocco, Fiji, and India due to consump-
tion of cooking oil contaminated with lubricating oil (con-
taining triorthocresyl phosphate).6–11
Neurologic syndromes following OP toxicity are highly
variable and depend on such factors as the speciﬁc OP
compound, dose and duration of exposure, species, age,
and various physiologic factors at the time of OP exposure.
Whereas acute OP toxicity usually produces acute cholin-
ergic crisis,7 acute cholinergic crises are often absent in
OPIDN. In contrast, OPIDN often begins with sensory
impairment, ataxia, weakness, muscle fasciculation, andhyporeﬂexia andmay progress to complete ﬂaccid paralysis
followed by progressive spastic paraplegia.4,7,12 Neuropath-
ologic analyses of OPIDN have shown distal degeneration
of the longest central- and peripheral-nervous-system
axons.1,12 Distal axon degeneration is also the primaryneu-
ropathologic feature of hereditary spastic paraplegia (HSP)
(reviewed in13). Some complicated forms of HSP,13 such as
Troyer syndrome (MIM 275900), also exhibit lower-motor
neuron involvement.14
OPIDN pathogenesis involves neuropathy target esterase
(NTE), a neuronal membrane protein, either through di-
rect OP-induced inhibition of NTE or through generation
of OP-NTE neurotoxic complexes (‘‘aged NTE’’). NTE’s
functions are incompletely understood. NTE is capable of
hydrolyzing several intrinsic membrane lipids and thus
may be a factor in determining the composition of neu-
ronal membranes.15 NTE’s catalytic domain for esterase
activity has been mapped to a 489 amino acid region
between residues 727 and 1216.16 Participation of NTE in
a cell-signaling pathway controlling interactions between
neurons and accessory glial cells in the developing nervous
system has also been proposed.17,18
We studied a consanguineous family of Ashkenazi Jewish
ancestry (Figure 1A) and a nonconsanguineous family of
northern European ancestry (Figure 1B) in which affected
subjects developed childhood onset of insidiously pro-
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Figure 1. NTE-MND Kindreds
Analyzed portions of NTE-MND kindreds are shown together with haplotypes for linked and flanking microsatellite markers. Letters for
marker NTE refer to the NTE sequence at cDNA position 3034 and cDNA position 2669 for the missense mutation and Ins for the insertion
at position 2946.
(A) Analyzed portion of index NTE-MND kindred.
(B) Second NTE-MND kindred: affected subjects have compound heterozygous NTE mutations.wasting of distal upper- and lower-extremity muscles. Elec-
trophysiologic studies were consistent with a motor axon-
opathy affecting upper and lower extremities. Magnetic
resonance imaging demonstrated spinal cord atrophy, par-
ticularly in the thoracic region. The affected phenotype in
each family conformed both to OPIDN and to ‘‘Troyer
syndrome,’’ an autosomal-recessive form of HSP associated
with distal muscle wasting.14,19 Troyer syndrome patients
variably exhibit additional neurologic and systemic abnor-
malities (delayed milestone acquisition, skeletal abnormal-Theities, and cerebellar, extrapyramidal, and cognitive impair-
ment). These features were not observed in our patients.
The University of Michigan Institutional Review Board
approved this study.
We analyzed the SPG20/spartin gene (MIM 607111) cod-
ing sequence, mutations in which cause Troyer syndrome
(SPG20 HSP),14,19 and found no mutations in the index
(consanguineous) family (data not shown), and we ex-
cluded the SPG2014 locus in the consanguineous family
by genetic-linkage analysis (Table 1). Two-point linkageAmerican Journal of Human Genetics 82, 780–785, March 2008 781
analyses for exclusion mapping were performed with the
MLINK subroutine of the LINKAGE program20 with an
autosomal-recessive model of disease inheritance and a
disease allele frequency of 0.001. We assigned a genetic
penetrance of 0.90 for LOD-score calculations.
Wethen initiatedgenome-wide linkageanalysis (Figure2)
in the larger, consanguineous family with ten subjects
(three living affected subjects, seven living unaffected sub-
jects, no spouses of descendants) and in the second smaller,
nonconsanguineous family. Marrying-in spouses were
asymptomatic and had no evidence of similar neurologic
disorders in their families. Maximum-likelihood estimates
of marker allele frequencies were estimated from all 15 sub-
jects in both families. The average number of alleles was 4
(range ¼ 3–7), and the average observed heterozygosity of
these markers in the families was 0.64 (range ¼ 0.32–0.84).
We analyzed 400 polymorphic microsatellite markers
spaced ~10 cM apart (ABI MD-10 Linkage Mapping Set),
of which 164markers heterozygous for at least one affected
individual excluded 41% of the genome. Six of these
markers were homozygous for all affected individuals in
the consanguineous family. We analyzed adjacent mark-
ers for each homozygous marker. Only markers adjacent
to D19S209 yielded an extended linked haplotype that
spanned 22 cM between D19S565 and D19S884 on chro-
mosome 19p13 (Figure 1A). In the smaller, nonconsangui-
neous family, these same markers also resulted in haplo-
type sharing in affected subjects consistent with genetic
linkage of this region (Figure 1B).
The positive chromosome 19 region was analyzed with
multipoint methods to incorporate information from all
27 informative markers. The GeneHunter program21 was
used to obtain exact multipoint LOD scores and multi-
point nonparametric linkage (NPL) scores. The NPL score
is based on allele sharing identical by descent (IBD) and
does not assume a transmission model. The NPL analysis
allows an assessment of the robustness of the result to
model misspeciﬁcation. Because of the size and complexity
of the largest pedigree, it had to be trimmed for analysis in
GeneHunter. Therefore, analyses were also performed with
SimWalk2.22–24 SimWalk2 uses Markov chain Monte Carlo
(MCMC) and simulated annealing methods to perform
multipoint analyses, allowing computation on large, com-
plex pedigrees. Although the method is not exact, all
Table 1. Genetic-Linkage Analysis Excludes Chromosome
13q12.3
Marker LOD q ¼ 0 0.01 0.02 0.03 0.04 0.05
D13S1841 3.4 1.23 0.94 0.77 0.66 0.57
D13S1842 2.19 1.19 0.92 0.76 0.64 0.56
D13S1851 3.4 1.23 0.94 0.77 0.66 0.57
D13S1843 3.4 1.23 0.94 0.77 0.66 0.57
D13S219 0.08 0.07 0.07 0.06 0.06 0.06
D13S1844 2.19 1.19 0.92 0.76 0.64 0.56
Genetic-linkage analysis excludes SPG20 ‘‘Troyer syndrome’’ locus on chro-
mosome 13q12.3.782 The American Journal of Human Genetics 82, 780–785, Marchpedigree members could be included in the analysis. We
performed parametric LOD score and NPL analyses in Sim-
Walk2. For each analysis, we set the ‘‘parallel runs’’ ﬂag to
generate two simulated annealing runs of the data. The
runs produced a maximum score at the same location
with the same scores within rounding error. p values given
by SimWalk2 were calculated with 10,000 simulations. For
nonparametric analyses, p values were used to generate the
reported scores (score ¼ log10 [p value]).
Multipoint LOD score and nonparametric analyses of
the two families clearly mirrored the shared haplotype re-
gion (Figure 2). With all methods (model-based parame-
tric analysis or nonparametric analysis with either Gene-
Hunter or SimWalk2) used, the maximum LOD score
occurred near marker D19S869. Maximum multipoint
parametric LOD scores were 2.58 with GeneHunter and
3.82 with SimWalk2. The maximum NPL scores were
3.30withGeneHunter and3.36withSimWalk2. Thepvalue
associated with the GeneHunter statistics is 0.002; the
simulation-based p value for the SimWalk2 statistics is
0.0004. The index family contributed most to these scores
(3.28 and 3.09 for the parametric andNPL SimWalk2 analy-
ses, respectively, and 2.07 and 3.07 for the GeneHunter
parametric and NPL analyses, respectively). It is important
to note that the second small, nonconsanguineous family
supported this peak, with scores close to the maximum
expected for an affected-sibling-pair family.
To further characterize the region on chromosome 19
and to fully characterize all shared chromosomal regions,
we carried out high-density SNP typing with the Affyme-
trix 250K NspI chips on all family members for whom
DNA was available: 12 subjects in the consanguineous
family (including all three affected individuals and two ad-
ditional unaffected subjects ascertained after the initial mi-
crosatellite linkage analysis had been performed) and ﬁve
subjects in the nonconsanguineous family. We analyzed
the SNP data by looking for regions of autozygosity in
the entire genome with the Find Autozygous Regions pro-
gram in the GeneSpring GTanalysis package (Agilent). The
results of this analysis are shown in Figure 3; they clearly
show a single major autozygosity region on chromosome
19 in the three affected individuals. This 4.7 megabase
region is deﬁned by the map location from 2784431 to
7541689 bp (NCBI build 35). This region corresponds to
the same region identiﬁed by the microsatellite markers.
The region includes the interesting candidate gene neurop-
athy target esterase (NTE) (GenBank AJ004832), whose
location on chromosome 19 is from 7505075—7532647
bp (UCSC Genome Browser on NCBI build 35).
TheNTEgenewas anobvious candidate becauseof its role
in OPIDN and the similarity of symptoms seen in our
patients to those reported forOPIDN.Analysis ofNTE’s cod-
ing sequence in the index family showed that each affected
subject was homozygous for (and each obligate carrier
heterozygous for) substitution of guanine for adenine at
NTE cDNA 3034. This mutation was absent in 105 control
subjects (data not shown) and caused substitution of valine2008
formethionine at aminoacidposition1012 (M1012V). This
mutation disrupts an interspecies conserved residue within
NTE’s catalytic domain (Figure 4C).25 Mouse, Drosophila,
and C. elegans species all contain M at residue 1012. Poly-
phen analysis of M1012Vmutation gave a PSIC proﬁle-dif-
ference score of 2.590 predicting that the mutation would
Figure 2. Multipoint Linkage Analysis of Chromosome 19
Markers
Multipoint analyses of markers on chromosome 19 show signif-
icant linkage regardless of platform (GeneHunter versus
SimWalk2) and analysis assumptions (parametric LOD-score
analysis versus nonparametric linkage [NPL]).
Figure 3. Autozygous Regions in NTE-MND Consanguine-
ous Kindred Identified from 250 K SNP Chips
Output figure from a GeneSpring GT program.
bedamaging.On theotherhand, SIFTanalysis predicted
that M1012V substitution would be tolerated.
We then analyzed the NTE coding sequence in the
second, unrelated, nonconsanguineous family (Fig-
ure 1B). Analysis of NTE’s coding sequence in affected
subjects in this second family showed that they were
compound heterozygotes for two NTE mutations. Like
the mutation in the index family, these mutations
also occurred within NTE’s catalytic domain. One allele
had a 2669G/A mutation corresponding to an R890H
substitution in NTE’s catalytic domain. Human and
mouse contain R at residue 890, whereas Drosophila
and C.elegans contain K at residue 890. Polyphen anal-
ysis (PSIC proﬁle-difference score ¼ 0.184) and SIFT
analysis predicted that R890H would be a tolerated sub-
stitution. The other allele had a four base pair insertion
(NTE mRNA position 2946) that caused a frameshift
and protein truncation after residue 1019. The trun-
cated protein is predicted to be missing the last 235 res-
idues of NTE’s catalytic domain (which extends from
amino acid position 727 to position 1216). These muta-
tions were present separately in each carrier parent and
absent in 105 control subjects and the unaffected sibling.
In summary, we identiﬁed homozygous and compound
heterozygous NTE mutations in subjects from two
unrelated families with autosomal-recessive progressive
spastic paraplegia associated with distal upper- and
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Figure 4. Disease-Specific Mutations in NTE-MND Kindreds
(A) Homozygous NTE mutation in consanguineous NTE-MND kindred.
(B) Compound-heterozygous NTE mutations in nonconsanguineous NTE-MND kindred.
(C) Disease-specific mutations in NTE-MND kindreds disrupt interspecies conserved residues in the NTE catalytic domain (shown in part).
The c.2946_2947insCAGC leads to a frameshift and premature truncation indicated by the sequence in red. Symbols below sequence
indicate the following: ‘‘*’’ indicates sequence identity; ‘‘:’’ indicates that one of strong groups is conserved; ‘‘.’’ indicates that one of
weak groups is conserved.lower-extremity wasting. Because of its clinical similarity
with SPG20 HSP (Troyer syndrome), we reserved for this
disease the next-available HSP locus designation (SPG39)
and refer to this disorder as NTE-related Motor Neuron Dis-
order (NTE-MND). These NTE mutations are disease-spe-
ciﬁc and considered pathogenic for several reasons. First,
they were present in affected subjects in two unrelated kin-
dreds and absent in control subjects. Second, they affect
amino acid residues within NTE’s catalytic domain. Third,
NTE plays a central role in OPIDN, an upper- and lower-
motor neuron disorder whose symptoms bear a striking
resemblance to those exhibited by our NTE-MND patients.
Two mechanisms for NTE involvement in OPIDN have
been proposed. The ﬁrst mechanism proposes that neuro-
toxicity is the consequence of OP-induced inhibition of
NTE. The second mechanism proposes that OP-NTE com-
plexes are toxic. These proposed mechanisms are not
mutually exclusive because OP interaction with NTE could
both be toxic as well as interfere with NTE activity. The fact
that identiﬁed NTE mutations in NTE-MND subjects dis-
turb NTE’s catalytic domain suggests that they could result
in altered NTE activity in vivo. This suggests that modiﬁed784 The American Journal of Human Genetics 82, 780–785, MarchNTE activity alone could be sufﬁcient to cause corticospi-
nal tract and peripheral motor axonopathy. Nonetheless,
it is also possible that the NTE mutations identiﬁed result
in neurotoxic or ‘‘aged’’ NTE.
Observations thatNTEmutations are associatedwithpro-
gressive upper- and lower-motor neuron disease indicate
the importance of NTE in maintaining the integrity of
corticospinal tract and peripheralmotor axons. The ﬁnding
thatNTEmutations underlie corticospinal tract andperiph-
eral motor axon degeneration raises the possibility that
other NTE polymorphisms (or genetic variation in factors
that regulate or interactwithNTE) could contribute toother
motor neuron disorders including amyotrophic lateral
sclerosis (ALS) and primary lateral sclerosis (PLS).
We have shown that two NTE mutations are the likely
cause of autosomal-recessive motor neuron disease that
closely resembles OPIDN. These NTEmutations were sufﬁ-
cient to cause the disorder even in the absence of apparent
exposure toneurotoxicOPcompounds. Itwill be important
to determine whether other polymorphisms in NTE and/or
proteins with which it interacts inﬂuence the susceptibility
to OP-induced neurologic disease. Our ﬁndings, together2008
with the recently identiﬁed association of PON1 polymor-
phismswithALS,26 further support the possibility that neu-
rotoxicOP compounds contribute tomotor neurondisease.
Supplemental Data
One table listing genescan data can be found online at http://
www.ajhg.org/.
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